期刊文献+

手性固定相HPLC法分离索氟布韦的对映异构体

A Chiral Stationary Phase HPLC Method for Enantiomers Separation in Sofosbuvir
下载PDF
导出
摘要 目的:建立索氟布韦对映异构体的检测方法。方法:采用CHIRALPAK AD-H 250×4.6 mm,5μm手性色谱柱,以正己烷-异丙醇(65∶35,体积比)为流动相;流速为0.5 mL/min,检测波长为260 nm,柱温为40℃。结果:索氟布韦与异构体之间最小分离度为3.9,且峰面积与浓度在一定的范围内均呈良好的线性关系。结论:该方法可用于索氟布韦与异构体的分离,并且专属性强、灵敏度高,能够准确、可靠的定量检测原料药中的异构体。 Objective:To establish a method for the determination of the enantiomers of sofosbuvir.Methods:A CHIRALPAK AD-H 250×4.6 mm 5μm chiral column was used with n-hexane-isopropanol(65∶35)as mobile phase.The flow rate was 0.5 mL/min,the detection wavelength was 260 nm,and the column temperature was 40℃.Results:The minimum separation degree between sofosbuvir and isomer was 3.9,and the linear relationship between the peak area and concentration was good in a certain range.Conclusion:The method can be used for the separation of sofosbuvir from isomers with high specificity and sensitivity,and can be used for the accurate and reliable quantitative determination of isomers in API.
作者 王艳 周君安 魏娜 Wang Yan;Zhou Jun′an;Wei Na(Research Institute of Jiangsu Hansoh Pharmaceutical Group Co.,Ltd.,Lianyungang 222069,China)
出处 《山东化工》 CAS 2022年第5期116-119,122,共5页 Shandong Chemical Industry
关键词 索氟布韦 高效液相色谱法 对映异构体分离 手性固定相 sofosbuvir HPLC enantiomers separation chiral stationary phase
  • 相关文献

参考文献3

二级参考文献16

  • 1FDA . SOFOSBUVIR [ EB/OL ]. [ 2013 - 12 - 06 ]. http :// www. accessdata, fda. gov/drugsatfda_ docs/label/2013/ 204671 s0001bl, pdf.
  • 2Carlota Reviriego GS-7977 [ J ]. Drugs Future ,2012,37 ( 3 ) : 175-182.
  • 3BRADLEY VINCE, JOHN M H, ERIC J L, et al. A random ized, double-blind, multiple-dose study of the pan-genotypie NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1,2,3 or 4 [J]. J Hepatol,2014,60(5) : 920-927.
  • 4KEATING, GILLIAN M. Vaidya, Asha Sofosbuvir : First Glo- bal Approval [ J]. Drugs,2014,74(2) :273-282.
  • 5FDA Advisory Committee Supports Appruval of Gilead' s Sofi sbuvir for Chronic Hepatitis C Infection[ EB/OL]. [ 2013-10-25 ] http :// www. drugs, corn/nda/sofosbuvir_l 31025. html.
  • 6U.S. Food and Drug Administration. FDA approves Sovaldi fiw chronic hepatitis C [ EB/OL]. [ 2013-12-06 ]. http://www, ida, gov/newsevents/newsroom/pressannouncements/ucm377888, htm.
  • 7WangFS , Fan JG , ZhangZ , et al. The global burden of liver disease : The maj or impact of China [ J ]. Hepatology, 2014,60 ( 6 ) : 2099-2108.
  • 8Ascher DB,Jerome Wielens J, Nero TL, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA [ J ]. Scientific Reports, 2014,4:4765-4777.
  • 9Sovaldi [ EB/OL]. [2014-12-24 ]. http://www, drugs, corn/search. php? searehterm = Harvard + Health + publication + Sovaldi.
  • 10U.S. Food and Drug Administration. FDA approves first cor flfination pill to treat hepatitis C[EB/OL]. [2014-10-10]. http://www, fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365, htm.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部